Oncotarget

Research Papers:

Functional FGFR4 Gly388Arg polymorphism contributes to cancer susceptibility: Evidence from meta-analysis

Si-Wei Xiong _, Jianqun Ma, Fen Feng, Wen Fu, Shan-Rong Shu, Tianjiao Ma, Caixia Wu, Guo-Chang Liu and Jinhong Zhu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:25300-25309. https://doi.org/10.18632/oncotarget.15811

Metrics: PDF 2194 views  |   HTML 2231 views  |   ?  


Abstract

Si-Wei Xiong1,*, Jianqun Ma2,*, Fen Feng3,*, Wen Fu4, Shan-Rong Shu5, Tianjiao Ma6, Caixia Wu7, Guo-Chang Liu4, Jinhong Zhu7

1Department of Urology, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou 510180, Guangdong, China

2Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin 150040, Heilongjiang, China

3Department of Gastroenterology, The First People’s Hospital of Foshan (Affiliated Foshan Hospital of Sun Yat-sen University), Foshan 528000, Guangdong, China

4Department of Pediatric Urology, Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou 510623, Guangdong, China

5Department of Gynecology and Obstetrics, The First Affiliated Hospital of Jinan University, Guangzhou 510630, Guangdong, China

6Department of Internal Medicine, Harbin Medical University, Harbin 150081, Heilongjiang, China

7Molecular Epidemiology Laboratory and Department of Laboratory Medicine, Harbin Medical University Cancer Hospital, Harbin 150040, Heilongjiang, China

*These authors have contributed equally to this work

Correspondence to:

Si-Wei Xiong, email: [email protected]

Jinhong Zhu, email: [email protected]

Keywords: FGFR4, Gly388Arg, polymorphism, cancer, meta-analysis

Received: November 09, 2016    Accepted: February 07, 2017    Published: February 28, 2017

ABSTRACT

Fibroblast growth factor receptor 4 (FGFR4) is a member of receptor tyrosine kinase family. A functional Gly388Arg (rs351855 G>A) polymorphism in FGFR4 gene causes a glycine-to-arginine change at codon 388 within the transmembrane domain of the receptor. Although the FGFR4 rs351855 G>A polymorphism has been implicated in cancer development, its association with cancer risk remains controversial. Here, we have systematically analyzed the association between the rs351855 G>A polymorphism and cancer risk by performing a meta-analysis of 27 studies consisting of 8,682 cases and 9,731 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association. The rs351855 G>A polymorphism was associated with an increased cancer risk under the recessive model (OR=1.19, 95% CI=1.01-1.41). Stratified analysis by cancer type indicated the rs351855 G>A polymorphism was associated with an increased risk of breast and prostate cancer, but a decreased risk of lung cancer. This meta-analysis demonstrates the FGFR rs351855 G>A polymorphism is associated with increased cancer risk and suggests it could potentially serve as a chemotherapeutic target or biomarker to screen high-risk individuals.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15811